Symbol Lookup

Friday December 09, 2016 11:59 PM ET. Data delayed 15 minutes.
9.87
0.03 (0.30%)
Bid/Lots
9.86/5
Ask/Lots
9.87/10
Open/Prev Close
9.72/9.84
Day Range
9.72-10.65
52-Week Range
4.26-17.69
Vol/Avg Daily Vol
1.2M/1.0M

TD Waterhouse offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

CARA Headlines

Go
Legal Cannabis Market is Gaining Attention
9:00AM ET on Thursday Dec 08, 2016 by PR Newswire
Companies Mentioned: INSY, CNZCF, GWPH, CARA, TWMJF

California is home to about 12 percent of Americans, and full legalization of cannabis in the state has been a major milestone for this young, still devolving industry. California will start issuing licenses in 2018, as a result analysts and researches have started to look into the potential of the market in the near future. Vivien Azer, a cannabis analyst with Cowen, has estimated that consumer spending in the legal cannabis market will grow to $50 billion by 2026. Canadian Zeolite Corp. (OTC: CNZCF) (TSX-V: CNZ.V), Cara Therapeutics Inc. (NASDAQ: CARA), GW Pharmaceuticals (NASDAQ: GWPH), Insys Therapeutics Inc. (NASDAQ: INSY), Canopy Growth Corporation (OTC: TWMJF)

California is home to about 12 percent of Americans, and full legalization of cannabis in the state has been a major milestone for this young, still devolving industry. California will start issuing licenses in 2018, as a result analysts and re...

Dec 5, 2016

Cannabis Sales to Grow Faster in Coming Years
8:55AM ET on Monday Dec 05, 2016 by PR Newswire
Companies Mentioned: CVSI, CIIX, MJNA, CARA, MDCL

After elections, another four states have voted in favor of legalization of cannabis for recreational purposes, including the state of California, which is the largest market for cannabis. Market analysts have been publishing analytical reports regarding the future of the legal cannabis market. According to a report by ArcView Market Research for example, is projecting that the cannabis sales will surpass $6.7 billion in sales in the United States this year. Sales are expected to grow to $21.8 billion by 2020. ChineseInvestors.com Inc. (OTC: CIIX), Medicine Man Technologies, Inc. (OTC: MDCL), CV Sciences Inc. (OTC: CVSI), Medical Marijuana Inc. (OTC: MJNA), Cara Therapeutics Inc. (NASDAQ: CARA)

After elections, another four states have voted in favor of legalization of cannabis for recreational purposes, including the state of California, which is the largest market for cannabis. Market analysts have been publishing analytical reports...

Nov 30, 2016

Cannabis Industry Expects to Become the Next Biggest Market
8:45AM ET on Wednesday Nov 30, 2016 by PR Newswire
Companies Mentioned: GRWG, INSY, GWPH, CARA, ZYNE

After historical elections earlier this month, other states may be reconsidering their stance on legalization of Cannabis for medical or recreational use. Currently, there are gaps among states concerning cannabis legalization reform and the difficulties for both the government and the businesses involved as 20 percent of Americans can now lawfully use Cannabis. GrowGeneration Corp. (OTC: GRWG), Insys Therapeutics Inc. (NASDAQ: INSY), GW Pharmaceuticals PLC (NASDAQ: GWPH), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Cara Therapeutics Inc. (NASDAQ: CARA).

After historical elections earlier this month, other states may be reconsidering their stance on legalization of Cannabis for medical or recreational use. Currently, there are gaps among states concerning cannabis legalization reform and the di...

Nov 29, 2016

Cara Therapeutics Completes Enrollment of Trial of I.V. CR845 to Treat Uremic Pruritus
8:37AM ET on Tuesday Nov 29, 2016 by MT Newswires
Companies Mentioned: CARA
08:37 AM EST, 11/29/2016 (MT Newswires) -- Cara Therapeutics (CARA), a biotechnology company, has completed patient enrollment for a trial of I.V. CR845 in dialysis patients suffering from moderate-to-severe uremic pruritus (UP). UP is an intractab...
08:37 AM EST, 11/29/2016 (MT Newswires) -- Cara Therapeutics (CARA), a biotechnology company, has completed patient enrollment for a trial of I.V. CR845 in dialysis patients suffering from moderate-to-severe uremic pruritus (UP). UP is an intrac...
Cara Therapeutics Completes Planned Enrollment of Eight-Week Multi-Dose Phase of Adaptive Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
8:00AM ET on Tuesday Nov 29, 2016 by GlobeNewswire
Companies Mentioned: CARA

- Part A of the trial will evaluate three doses of I.V. CR845 versus placebo in 160 dialysis patients -

- Top-line data expected in first quarter of 2017 -

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has completed patient enrollment for the multi-dose phase of its adaptive Phase 2/3 trial of I.V. CR845 in dialysis patients suffering from moderate-to-severe uremic pruritus (UP). UP is an intractable systemic itch condition in patients with chronic kidney disease (CKD), for which there are no approved therapies in the United States.

- Part A of the trial will evaluate three doses of I.V. CR845 versus placebo in 160 dialysis patients -

- Top-line data expected in first quarter of 2017 -

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused ...

← Newer123Older →

Peers Headlines

Today

BRIEF-Proteostasis Therapeutics - Co received notice from Biogen of termination of collaborative research, development, commercialization, license agreement
1 hour ago by Thomson Reuters
Companies Mentioned: BIIB, PTI

Dec 9 (Reuters) - Proteostasis Therapeutics Inc

* Proteostasis Therapeutics - on Dec 5, co received notice from biogen of termination of collaborative ...

Dec 6, 2016

Stemline Therapeutics Down 4.5% After Co Presents SL-401 Lead-In Data
12:41PM ET on Tuesday Dec 06, 2016 by MT Newswires
Companies Mentioned: STML
12:41 PM EST, 12/06/2016 (MT Newswires) -- Stemline Therapeutics (STML) slumps 4.5% after the company said it presented SL-401 lead-in data from its ongoing Phase 2 trial in acute myeloid leukemia (AML) in remission with minimal residual disease ...
BRIEF-Stemline Therapeutics says SL-401 Phase 2 trial in AML results found SL-401 to be safe, well tolerated
11:57AM ET on Tuesday Dec 06, 2016 by Thomson Reuters
Companies Mentioned: STML

Dec 6 (Reuters) - Stemline Therapeutics Inc :

* SL-401 was found to be safe and well tolerated, and side effects were predictable and manageable

* Steml...

Stemline Therapeutics Presents SL-401 Lead-in Results from its Ongoing Phase 2 Trial in AML in Remission with MRD and Phase 2 Trial in High-Risk Myeloproliferative Neoplasms (MPN) at ASH
11:48AM ET on Tuesday Dec 06, 2016 by GlobeNewswire
Companies Mentioned: STML

Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the presentation of SL-401 lead-in data from its ongoing Phase 2 trial in acute myeloid leukemia (AML) in remission with minimal residual disease (MRD) and ongoing Phase 2 trial in high-...

Dec 5, 2016

Stemline Therapeutics' SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASH; High Response Rates Maintained Across All Lines
12:48PM ET on Monday Dec 05, 2016 by GlobeNewswire
Companies Mentioned: STML

Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the oral presentation of positive clinical data from its ongoing SL-401 Phase 2 potentially pivotal clinical trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN). The trial resu...

Dec 2, 2016

Stemline Announces Seven Presentations, Including Oral Presentation of Updated SL-401 Phase 2 BPDCN Data, at the 2016 ASH Meeting this Weekend
7:30AM ET on Friday Dec 02, 2016 by GlobeNewswire
Companies Mentioned: STML

Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that SL-401, a novel targeted therapeutic directed to CD123, will be featured in seven presentations, including three oral presentations, at the 2016 American Society of Hematology (ASH)...

Ignyta Reports On Tumor-Fighting Drug Combination At Cancer Symposium
6:36AM ET on Friday Dec 02, 2016 by MT Newswires
Companies Mentioned: RXDX
06:36 AM EST, 12/02/2016 (MT Newswires) -- Ignyta (RXDX) said Friday it presented data examining the combination of the drugs entrectinib and trametinib in fighting certain types of tumors at the Molecular Targets and Cancer Therapeutics Symposiu...

Dec 1, 2016

Ignyta Sees 56% Preliminary Objective Response Rate In Solid Tumor Patients Treated With Cancer Drug
6:28AM ET on Thursday Dec 01, 2016 by MT Newswires
Companies Mentioned: RXDX
06:28 AM EST, 12/01/2016 (MT Newswires) -- Ignyta (RXDX), a biotechnology company, said Thursday it has seen a preliminary objective response rate of 56% in certain cancer patients treated with its RXDX-105. A total of five out of nine patients...

Nov 29, 2016

Ignyta Says Pre-Clinical Study Show RXDX-106 Inhibits Tumor Growth
6:14AM ET on Tuesday Nov 29, 2016 by MT Newswires
Companies Mentioned: RXDX
06:14 AM EST, 11/29/2016 (MT Newswires) -- Ignyta (RXDX) Tuesday said preclinical data showed RXDX-106 inhibited TAM-mediated and c-MET-mediated tumor growth in vivo while data on RXDX-105 demonstrated significant anti-tumor activity in models ha...
Esperion Therapeutics Announces Publication of Definitive Paper on Bempedoic Acid Mechanism of Action in Nature Communications
12:02AM ET on Tuesday Nov 29, 2016 by GlobeNewswire
Companies Mentioned: ESPR

Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today announced the publicatio...

← Newer123Older →